Pharmacovigilance & Post-Market Compliance
Checklist for safety database compliance before major PV inspections
Checklist for Safety Database Compliance Before Major PV Inspections Checklist for Safety Database Compliance Before Major PV Inspections In the evolving field of pharmacovigilance (PV), maintaining compliance with regulatory expectations is paramount. With the increasing scrutiny from regulatory bodies, particularly the US FDA and its counterparts in the EU and UK, it becomes essential for pharma professionals to ensure that their safety databases are meticulously prepared for major PV inspections. This tutorial provides a comprehensive checklist designed to assist clinical operations, regulatory affairs, and medical affairs professionals in achieving regulatory compliance, particularly in the areas of case processing, MedDRA coding,…
Implementing change control for safety database upgrades and migrations
Implementing Change Control for Safety Database Upgrades and Migrations In the realm of pharmacovigilance, the integrity and reliability of safety databases is paramount. As updates and migrations become necessary, implementing a robust change control process ensures compliance with regulatory mandates and maintains data integrity. This article serves as an in-depth tutorial for pharmaceutical professionals involved in safety database management, focusing on the required steps to incorporate change control effectively. 1. Understanding Change Control in Pharmacovigilance Change control refers to the systematic approach to managing all changes made to a product or system. When it comes to safety database upgrades, change…
Global product dictionary and configuration governance in PV systems
Global Product Dictionary and Configuration Governance in Pharmacovigilance Systems Pharmacovigilance (PV) encompasses a range of activities aimed at monitoring the safety of pharmaceutical products and ensuring that the benefits outweigh the risks once they are marketed. Within this critical domain, the governance of global product dictionaries and configuration plays a vital role. This article serves as a detailed tutorial designed to guide pharmaceutical professionals and regulatory affairs stakeholders through essential aspects of case processing, MedDRA coding, and safety database compliance, as aligned with US FDA regulations and pertinent practices in the UK and EU. Understanding the Global Product Dictionary in…
How to handle product quality complaints that generate safety cases
How to handle product quality complaints that generate safety cases How to Handle Product Quality Complaints That Generate Safety Cases In the biopharmaceutical industry, the timely and effective handling of product quality complaints that may lead to safety cases is paramount for ensuring patient safety and regulatory compliance. This article provides a detailed, step-by-step tutorial designed for pharma professionals working in clinical operations, regulatory affairs, and medical affairs across the US, UK, and EU markets. Understanding the Regulatory Framework Before diving into the specific processes involved in handling product quality complaints, it is essential to understand the regulatory framework surrounding…
Key PV processes regulators scrutinise most during on site inspections
Key Pharmacovigilance Processes Regulators Scrutinize During On-Site Inspections Pharmacovigilance (PV) audits are critical to maintaining drug safety and efficacy. Regulatory authorities such as the FDA, MHRA, and EMA scrutinize various PV processes during on-site inspections to ensure compliance with pharmacovigilance regulations. In this article, we will outline the key PV processes that regulators pay close attention to, helping healthcare professionals understand the importance of these audits and inspections in fostering a culture of inspection readiness. Understanding Pharmacovigilance Audits and Inspections The primary objective of pharmacovigilance audits and inspections is to ensure that the safety and efficacy of a pharmaceutical product…
Mock PV inspection playbook for global safety organisations
Mock PV Inspection Playbook for Global Safety Organisations Pharmacovigilance (PV) is an intricate component of drug safety that ensures the well-being of patients through the continuous monitoring of pharmaceuticals on the market. As regulatory authorities like the FDA, MHRA, and EMA are increasingly scrutinizing these processes, organizations must prepare for pharmacovigilance audits and inspections meticulously. This article serves as a comprehensive mock inspection playbook, emphasizing the significance of a robust inspection readiness culture and providing step-by-step guidance for organizations to ensure compliance and readiness. Understanding Pharmacovigilance Audits and Inspections Pharmacovigilance audits and inspections are vital activities that validate the compliance…
Designing an inspection ready pharmacovigilance system master file PSMF
Designing an Inspection Ready Pharmacovigilance System Master File PSMF Designing an Inspection Ready Pharmacovigilance System Master File PSMF In the current landscape of drug development and post-marketing surveillance, having a robust Pharmacovigilance System Master File (PSMF) is critical for ensuring that organizations meet regulatory requirements and maintain a state of inspection readiness. The PSMF serves as a central repository of information about the pharmacovigilance system and is an essential tool for demonstrating compliance during audits and inspections by the FDA, MHRA, and EMA. This step-by-step tutorial will guide you through the process of designing an inspection-ready PSMF, addressing key areas…
Common FDA and EMA pharmacovigilance inspection findings and how to avoid them
Common FDA and EMA pharmacovigilance inspection findings and how to avoid them Common FDA and EMA Pharmacovigilance Inspection Findings and How to Avoid Them Pharmacovigilance (PV) is a critical aspect of medicine regulation, ensuring the safety of pharmaceuticals post-market. Regulatory bodies such as the US FDA and the EMA are charged with safeguarding public health by monitoring adverse drug reactions (ADRs) and ensuring compliance with safety standards. This article will outline common inspection findings during pharmacovigilance audits conducted by the FDA and EMA, and provide detailed strategies to avoid these pitfalls. Understanding the Importance of Pharmacovigilance Audits Pharmacovigilance audits play…
Typical MHRA pharmacovigilance findings and what they mean for sponsors
Understanding Typical MHRA Pharmacovigilance Findings and Their Implications for Sponsors Pharmacovigilance (PV) is an essential aspect of clinical research and post-market surveillance that helps ensure drug safety and efficacy. In this comprehensive tutorial, we will explore typical findings from pharmacovigilance audits, particularly from the Medicines and Healthcare products Regulatory Agency (MHRA), and examine their implications for sponsors. While the primary focus will be on MHRA practices, comparisons with FDA and EMA regulations will also be provided where relevant. 1. Overview of Pharmacovigilance Audits Pharmacovigilance audits are structured evaluations of a sponsor’s PV systems to ensure compliance with regulatory requirements and…
PV audit programmes for affiliates, partners and service providers
PV Audit Programmes for Affiliates, Partners and Service Providers Comprehensive Guide to PV Audit Programmes for Affiliates, Partners and Service Providers Introduction to Pharmacovigilance Audits Pharmacovigilance (PV) audits are an essential component in the oversight of drug safety and efficacy within the pharmaceutical industry. They ensure that companies meet the regulatory requirements set forth by governing bodies such as the FDA, the MHRA in the United Kingdom, and the EMA in the European Union. These audits serve to evaluate the activities related to drug safety monitoring and help organizations maintain compliance with applicable regulations. Pharmaceutical companies routinely engage with affiliates,…